MedTrace Logo

The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation

NCT00789516 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2013-03-07

No results posted yet for this study

Summary

Hypercoagulable state is well recognized in patients with β-thalassemia. Evidences of hypercoagulability include abnormal expression of phosphatidylserine on red blood cell (rbc) surface and consequent increased platelet activation and thrombin generation. In addition, a reduction of anticoagulants i.e. proteins C and S and antithrombin (AT) was demonstrated. However, coagulable state in patients with β-thalassemia following stem cell transplantation (SCT) has not been characterized.

Conditions

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Nongnuch Sirachainan, MD · Ramathibodi Hospital, Mahidol University

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2009-03-31
Completion
2009-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00789516 on ClinicalTrials.gov